SB 202190 (FHPI) is a p38 MAPK inhibitor that inhibits p38alpha and p38beta2 (IC50=50/100 nM) selectively and cell-permeably. SB 202190 has antitumor activity and also induces the differentiation of human embryonic stem cells into cardiomyocytes.
Molecular Weight:
331.34
Purity:
99.84%
CAS Number:
[152121-30-7]
Formula:
C20H14FN3O
Target:
p38 MAPK|||Autophagy|||Apoptosis
T2301
* VAT and and shipping costs not included. Errors and price changes excepted